Inobrodib

Overview

Inobrodib (CCS1477) is an orally active, potent, and selective inhibitor of the p300/CBP bromodomain . Inobrodib binds to p300 and CBP with K d values of 1.3 and 1.7 nM, respectively, and with 170/130-fold selectivity compared with BRD4 with a K d of 222 nM. CCS1477 inhibits cell proliferation in prostate cancer cell lines and decreases androgen receptor (AR)- and C-MYC-regulated gene expression.

Application

Products | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Respiratory Cancer | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Non-Small Cell Lung Cancer | Products > Disease Areas > Metastatic Breast Cancer | Products > Disease Areas > Metastatic Prostate Cancer | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Respiratory Disease | Products > Signaling Pathways > PROTAC | Products > Signaling Pathways > Epigenetics | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Ligands for Target Protein for PROTAC | Products > Signaling Pathways > Epigenetic Reader Domain | Products > Signaling Pathways > Histone Acetyltransferase

Product Information

• Catalog No.: HY-111784
• CAS No.: 2222941-37-7
• Molecular Formula: C30H32F2N4O3
• Molecular Weight: 534.60
• Purity: 99.95%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.5 mg/mL (4.68 mM); Clear solution
• Availability: In-stock

Source

Original product source